Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 910, doi. 10.1007/s12325-021-01998-y
- By:
- Publication type:
- Article
Works matching IS 0741238X AND DT 2022 AND VI 39 AND IP 2
Results: 19
1
2
Correction to: An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
3
Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 1055, doi. 10.1007/s12325-021-02016-x
- By:
- Publication type:
- Article
4
Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 1033, doi. 10.1007/s12325-021-02017-w
- By:
- Publication type:
- Article
5
Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 1045, doi. 10.1007/s12325-021-02014-z
- By:
- Publication type:
- Article
6
Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 1081, doi. 10.1007/s12325-021-02009-w
- By:
- Publication type:
- Article
7
Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 992, doi. 10.1007/s12325-021-02008-x
- By:
- Publication type:
- Article
8
White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 833, doi. 10.1007/s12325-021-01996-0
- By:
- Publication type:
- Article
9
The Epidemiology of Persons Living with Fontan in 2020 and Projections for 2030: Development of an Epidemiology Model Providing Multinational Estimates.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 1004, doi. 10.1007/s12325-021-02002-3
- By:
- Publication type:
- Article
10
Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 862, doi. 10.1007/s12325-021-01924-2
- By:
- Publication type:
- Article
11
The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 943, doi. 10.1007/s12325-021-01913-5
- By:
- Publication type:
- Article
12
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 845, doi. 10.1007/s12325-021-01989-z
- By:
- Publication type:
- Article
13
Measuring Burden of Illness in Phenylketonuria (PKU): Development of the PKU Symptom Severity and Impacts Scale as a Robust Patient-Reported Outcome.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 971, doi. 10.1007/s12325-021-01986-2
- By:
- Publication type:
- Article
14
Individualized HbA<sub>1c</sub> Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 1016, doi. 10.1007/s12325-021-01985-3
- By:
- Publication type:
- Article
15
Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 1068, doi. 10.1007/s12325-021-01981-7
- By:
- Publication type:
- Article
16
An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 892, doi. 10.1007/s12325-021-01975-5
- By:
- Publication type:
- Article
17
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 959, doi. 10.1007/s12325-021-01972-8
- By:
- Publication type:
- Article
18
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 923, doi. 10.1007/s12325-021-01971-9
- By:
- Publication type:
- Article
19
Correction to: Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria: The Prospective, Observational ACO Japan Cohort Study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice